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A B S T R A C T
Allergic reactions to antiepileptic drugs in the form of skin rash are not uncommon but angioedema, an
acute life threatening reaction is rare. Angioedema has been reported with the use of oxcarbazepine and
carbamazepine. We report a case of a 33-year-old woman with focal epilepsy who developed
angioedema following levetiracetam monotherapy. The patient had previous skin rashes with both
phenytoin and lamotrigine. Levetiracetam was stopped and she improved after treatment with
norepinephrine, antihistamines and corticosteroids.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Hypersensitivity to antiepileptic drugs (AEDs) can occur as an
idiosyncratic reaction. It is unpredictable and not dose related.
Several different hypersensitivity reactions have been reported
with AEDs. The most common type of adverse reaction is mild skin
rash.1 More serious reactions can also occur as toxic epidermal
necrolysis, Stevens–Johnson syndrome or Drug Reaction with
Eosinophilia and Systemic Symptoms (DRESS). Another uncom-
mon acute life threatening allergic reaction is angioedema.
Many drug hypersensitivity reactions result from reactive drug
metabolites and reﬂect either a direct cytotoxic effect or a
triggered immune response.1 Immune mediated hypersensitivity
reactions are classiﬁed as B cell or T cell mediated. Type I, II and III
reactions are B cell mediated. In type I reaction, an antigen binds to
IgE on mast cells and basophils resulting in degranulation and
release of inﬂammatory mediators. Type II reaction is a comple-
ment mediated reaction in which IgG or IgM bind to an antigen on
the surface of the cells causing cell lysis. Type III reaction involves
deposition of immune complex on different tissues causing
vascuilitis and tissue damage.
Type IV reaction is considered to be T cell mediated in which
antigen binds covalently to a Major Histocompitability Complex
(MHC) on the antigen presenting cells (APC) subsequently
triggering a delayed hypersensitivity reaction. Another mechanism
may involve antigen/T cell/MHC interaction through noncovalent
binding.1* Corresponding author. Tel.: +966 500787272; fax: +966 25323218.
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ity reactions are secondary to MHC dependent clonal T cell
proliferation.2 This has been documented with carbamazepine,
valproic acid and lamotrigine induced hypersensitivity reactions.2
Although antiepileptic hypersensitivity reaction is commonly
seen with therapy using older anticonvulsants, we report a case of
a woman who developed angioedema related to levetiracetam
monotherapy.
2. Case
A 33-year-old left handed woman had a generalized tonic clonic
seizure at age 19 years and another at age 29 years. She then
continued to have seizures once per month starting as a raising
epigastric sensation, followed by loss of awareness, staring, lip
smacking and bimanual automatisms progressing to a generalized
tonic clonic seizure. She was a product of full term pregnancy with
normal delivery. There was no history of febrile seizure, CNS
infection or head trauma. Her neurological examination was
unremarkable. EEG showed left temporal slowing. MRI revealed
the presence of bilateral periventricular heterotopia.
Initial treatment with carbamazepine then valproic acid was
not tolerated because of side effects. She was then maintained on
phenytoin for several years but because of ongoing seizures
topiramate was added. Since seizures remained unchanged,
lamotrigine was slowly substituted for topiramate. When she
reached 200 mg daily of lamotrigine a maculopapular skin rash
developed and persisted until lamotrigine was discontinued. A
return to phenytoin monotherapy then resulted in an intermittent
skin rash occurring daily shortly after she took her medication.
When she was admitted to the Epilepsy Monitoring Unit forvier Ltd. All rights reserved.
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discontinued and her rash disappeared.
Seizures proved unlocalizable with scalp EEG during monitor-
ing and she was placed on levetiracetam 500 mg daily as
monotherapy. She was on no other medications and had been
off phenytoin for one week. After the ﬁrst dose of levetiracetam she
developed a generalized maculopapular skin rash with associated
swelling of the face, lips and tongue. Her blood pressure and O2
saturation remained normal. CBC including eosinophils and
immunology remained normal. Levetiracetam was discontinued
and she was treated with IV norepinephrine, methylprednisone
and antihistamines. The swelling of her lips and tongue resolved
within 24 h and her skin rash disappeared in 3 days. Clobazam
30 mg daily was started which she tolerated well with no major
side effects. She is to be readmitted for stereotaxic depth recording
from her heterotopic tissue as well from the temporal lobes.
3. Discussion
Adverse drug reactions to AEDs in the form of skin rash have an
incidence of 3–15%.1,3 The risk of developing such a reaction is
higher with the use of aromatic AEDs such as phenobarbitol,
phenytoin and carbamazepine. However lamotrigine, a non-
aromatic AED, is also associated with a high frequency of skin
rash especially if it is introduced rapidly.4 The spectrum of allergic
reaction varies from simple skin rash to more severe forms of
Stevens–Johnson syndrome, toxic epidermal necrolysis or DRESS.5
The latter, ﬁrst described as a hypersensitivity reaction to AEDs,
is characterized by rash, fever, pharyngitis, lymphadenopathy,
eosinophilia and multiple organ dysfunction including hepatitis,
nephritis, pneumonitis and encephalitis. With the exception of
lamotrigine, newer AEDs such as levetiracetam have a much lower
risk of developing allergic reactions than the older drugs. A recent
case report of dose related drug eruption to levetiracetam has been
described.6
Angioedema is an allergic reaction similar in appearance to
urticaria (hives) in which patients develop localized swelling in the
dermis and submucosa.7 It can be life threatening due to airway
obstruction from laryngeal edema. Most commonly reported in
patients taking angiotensin converting enzyme inhibitors or
angiotensin receptor blockers, it occurs with a number of drugs.8
Angioedema results from a Type I immune mediated hypersensi-
tivity reaction when antigens to which the patient is sensitive bind
to IgE on the surface of basophils and mast cells causing
degranulation and release of inﬂammatory mediators.
Although skin rashes are not uncommon with AEDs, the more
serious reaction of angioedema is uncommon. Angioedema has
been reported after oxcarbazepine9 and carbamazepine adminis-
tration.10 This is the ﬁrst report of angioedema from levetiracetam.
Cross-sensitivity to AEDs, as occurred in our patient, is more
often encountered with aromatic AEDs such as phenytoin,
phenobarbital, carbamazepine, oxcarbazepine and lamotrigine.
There is a ﬁve times greater risk of allergic rash in patients with a
past history of AED induced rash.5 The rate of cross sensitivity toother aromatic AEDs may be as high as 71% between carbamaze-
pine and oxcarbazepine.11 Cross sensitivity between aromatic
AEDs and lamotrigine is around 20%.11 Although there are no
reports of cross sensitivity between levetiracetam and other AEDs,
this case appears to demonstrate cross sensitivity between
phenytoin, lamotrigine and levetiracetam.
Our patient developed an allergic rash to lamotrigine and
subsequently had rash with phenytoin as well despite having
taken the drug for several years before she became allergic to it.
Late onset allergic reaction to a previously tolerated drug is a rare
occurrence. Klassen reported a patient who tolerated phenytoin for
6 months before the introduction of carbamazepine.12 The patient
developed a hypersensitivity reaction which disappeared when
both drugs were discontinued. However reintroduction of
phenytoin resulted in diffuse skin rash after 2 doses. Gaig reported
5 cases of patients with anticonvulsant hypersensitivity reactions
who developed an allergic reaction to other chemically unrelated
drugs that were administrated during the episode of anticonvul-
sant hypersensitivity.13 In our patient we think that lamotrigine
induced an inﬂammatory immune response that subsequently
lead to phenytoin and levetiracetam hypersensitivity.
Although the newer antiepileptic drugs such as levetiracetam
are generally considered to be safe to use in patients who have had
an allergic reaction to aromatic AEDs, they still should be used with
caution. In patients with prior AED hypersensitivity, the introduc-
tion of a new medication should be done slowly and with careful
monitoring.
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